Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To evaluate drug survival of the tumor necrosis factor α inhibitors (TNFi) and risk factors for the drug discontinuation in patients with ankylosing spondylitis (AS). Methods: We retrospectively evaluated 487 AS patients at a single tertiary hospital. Among the TNFi users, drug survival and risk factors of TNFi discontinuation were investigated. Results: Among 487 patients, 128 AS patients were treated with at least one TNFi. Patients who were treated with TNFi were younger at disease onset, had more peripheral manifestations, and had higher level of acute phase reactants and body mass index than those of TNFi non-users at baseline. Of 128 patients, 28 patients (21.9%) discontinued first TNFi therapy during the follow-up period of 65.1 ± 27.9 months. In the multivariable analysis, female (hazard ratio [HR], 6.08; 95% confidence interval [CI], 2.27 to 16.27; p = 0.003), hip involvement (HR, 2.52; 95% CI, 1.08 to 5.87; p = 0.033) and a high C-reactive protein (CRP; HR, 1.10; 95% CI, 1.00 to 1.21; p = 0.044) were risk factors for drug discontinuation. Etanercept showed better survival rate than infliximab. The main reason for discontinuation of TNFi was inefficacy. Conclusions: TNFi discontinuation rate of Korean patients with AS seems to be similar to those with the European patients. Female sex, hip involvement, CRP, and the type of TNFi were associated with TNFi discontinuation.
Abstract
Background/Aims: To evaluate drug survival of the tumor necrosis factor α inhibitors (TNFi) and risk factors for the drug discontinuation in patients with ankylosing spondylitis (AS). Methods: We retrospectively evaluated 487 AS patients at a single tertiary hospital. Among the TNFi users, drug survival and risk factors of TNFi discontinuation were investigated. Results: Among 487 patients, 128 AS patients were treated with at least one TNFi. Patients who were treated with TNFi were younger at disease onset, had more peripheral manifestations, and had higher level of acute phase reactants and body mass index than those of TNFi non-users at baseline. Of 128 patients, 28 patients (21.9%) discontinued first TNFi therapy during the follow-up period of 65.1 ± 27.9 months. In the multivariable analysis, female (hazard ratio [HR], 6.08; 95% confidence interval [CI], 2.27 to 16.27; p = 0.003), hip involvement (HR, 2.52; 95% CI, 1.08 to 5.87; p = 0.033) and a high C-reactive protein (CRP; HR, 1.10; 95% CI, 1.00 to 1.21; p = 0.044) were risk factors for drug discontinuation. Etanercept showed better survival rate than infliximab. The main reason for discontinuation of TNFi was inefficacy. Conclusions: TNFi discontinuation rate of Korean patients with AS seems to be similar to those with the European patients. Female sex, hip involvement, CRP, and the type of TNFi were associated with TNFi discontinuation.
참고문헌 (33)
- Braun J, "Use of immunohisto logic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis", Arthritis Rheum, 38, pp.499~505 (1995)[DOI]
- Francois RJ, "Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases", Ann Rheum Dis, 65, pp.713~720 (2006)[DOI]
- Braun J, "Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial", Lancet, 359, pp.1187~1193 (2002)[DOI]
- Gorman JD, "Treatment of ankylos ing spondylitis by inhibition of tumor necrosis factor alpha", N Engl J Med, 346, pp.1349~1356 (2002)[DOI]
- van der Heijde D, "Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 54, pp.2136~2146 (2006)[DOI]
- Machado MA, "Treatment of ankylosing spondylitis with TNF blockers: a metaanalysis", Rheumatol Int, 33, pp.2199~2213 (2013)[DOI]
- Scire CA, "Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database", Clin Exp Rheumatol, 31, pp.857~863 (2013)
- van der Linden S, "Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria", Arthritis Rheum, 27, pp.361~368 (1984)[DOI]
- MacKay K, "The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index", J Rheumatol, 27, pp.2866~2872 (2000)
- Amor B, "Predictive factors for the longterm outcome of spondyloarthropathies", J Rheumatol, 21, pp.1883~1887 (1994)
- Deng Y, "Adipokines as novel biomarkers and regulators of the metabolic syndrome", Ann N Y Acad Sci, 1212, pp.E1~E19 (2010)
- Park MC, "Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis", Scand J Rheumatol, 36, pp.101~106 (2007)[DOI]
- Kim KJ, "Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis", Clin Rheumatol, 31, pp.1231~1238 (2012)[DOI]
- Glintborg B, "Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry", Ann Rheum Dis, 69, pp.2002~2008 (2010)[DOI]
- Konttinen L, "Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience", Clin Rheumatol, 26, pp.1693~1700 (2007)[DOI]
- Heiberg MS, "The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study", Arthritis Rheum, 59, pp.234~240 (2008)[DOI]
- Lie E, "Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register", Ann Rheum Dis, 70, pp.157~163 (2011)[DOI]
- Vander Cruyssen B, "Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery", Rheumatology (Oxford), 49, pp.73~81 (2010)[DOI]
- Poddubnyy D, "Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis", Arthritis Rheum, 64, pp.1388~1398 (2012)[DOI]
- Chen HA, "Factors associated with radiographic spinal involvement and hip involvement in ankylosing spondylitis", Semin Arthritis Rheum, 40, pp.552~558 (2011)[DOI]
- Neovius M, "Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab", Ann Rheum Dis, 74, pp.354~360 (2015)[DOI]
- Lee W, "Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort", Ann Rheum Dis, 66, pp.633~638 (2007)[DOI]
- Sokka T, "Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study", Arthritis Res Ther, 11, pp.R7~ (2009)
- Katz PP, "Differences in symptom reports between men and women with rheumatoid arthritis", Arthritis Care Res, 9, pp.441~448 (1996)[DOI]
- Marchesoni A, "TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice", Ann N Y Acad Sci, 1173, pp.837~846 (2009)[DOI]
- Gulyas K, "Real-life experience with switching TNF-<TEX>${\alpha}$<", TEX> inhibitors in ankylosing spondylitis, 2014, pp.15(Suppl 1), S93~S100
- Hackshaw A, "Small studies: strengths and limitations", Eur Respir J, 32, pp.1141~1143 (2008)[DOI]
- Plasencia C, "Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab", Ann Rheum Dis, 71, pp.1955~1960 (2012)[DOI]
- Maneiro JR, "Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis", JAMA Intern Med, 173, pp.1416~1428 (2013)[DOI]
- Arends S, "The formation of autoantibodies and antibodies to TNF-<TEX>${\alpha}$<", TEX> blocking agents in relation to clinical response in patients with ankylosing spondylitis, 2010, pp.28, 661~668
- Plasencia C, "The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients", Arthritis Res Ther, 15, pp.R79~ (2013)[DOI]
- Garces S, "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis", Ann Rheum Dis, 72, pp.1947~1955 (2013)[DOI]
- Lie E, "The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study", Ann Rheum Dis, 74, pp.970~978 (2015)[DOI]